Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A registrational bioequivalence study of APL 130227 (sublingual apomorphine) for Parkinson's disease.

Next Previous
Search
Trial Profile

A registrational bioequivalence study of APL 130227 (sublingual apomorphine) for Parkinson's disease.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 21 Oct 2016 This trial was planned by Cynapsus Therapeutics . The Company has now been acquired by Sunovion Pharmaceuticals , according to a Sunovion Pharmaceuticals media release.
  • 04 Apr 2016 According to Cynapsus media release, company plans to file NDA with the FDA near the end of 2016 or in early 2017.
  • 26 Apr 2013 Planned End Date changed from 1 Sep 2013 to 1 Mar 2014, as reported in a Cynapsus Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top